Silverback Therapeutics (SBTX) Competitors $13.55 -0.24 (-1.74%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends SBTX vs. MNKD, IRON, HRMY, NAMS, EVO, GPCR, ARVN, XNCR, GLPG, and NRIXShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include MannKind (MNKD), Disc Medicine (IRON), Harmony Biosciences (HRMY), NewAmsterdam Pharma (NAMS), Evotec (EVO), Structure Therapeutics (GPCR), Arvinas (ARVN), Xencor (XNCR), Galapagos (GLPG), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical preparations" industry. Silverback Therapeutics vs. MannKind Disc Medicine Harmony Biosciences NewAmsterdam Pharma Evotec Structure Therapeutics Arvinas Xencor Galapagos Nurix Therapeutics MannKind (NASDAQ:MNKD) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends. Which has higher valuation and earnings, MNKD or SBTX? MannKind has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannKind$198.96M9.63-$11.94M$0.0799.29Silverback TherapeuticsN/AN/A-$89.48M-$2.42-5.60 Does the media refer more to MNKD or SBTX? In the previous week, MannKind had 4 more articles in the media than Silverback Therapeutics. MarketBeat recorded 4 mentions for MannKind and 0 mentions for Silverback Therapeutics. MannKind's average media sentiment score of 0.38 beat Silverback Therapeutics' score of 0.00 indicating that MannKind is being referred to more favorably in the media. Company Overall Sentiment MannKind Neutral Silverback Therapeutics Neutral Do analysts rate MNKD or SBTX? MannKind presently has a consensus price target of $8.67, suggesting a potential upside of 24.70%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Silverback Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer MNKD or SBTX? MannKind received 561 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 60.12% of users gave MannKind an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote. CompanyUnderperformOutperformMannKindOutperform Votes57960.12% Underperform Votes38439.88% Silverback TherapeuticsOutperform Votes1856.25% Underperform Votes1443.75% Is MNKD or SBTX more profitable? MannKind has a net margin of 8.07% compared to Silverback Therapeutics' net margin of 0.00%. MannKind's return on equity of -17.74% beat Silverback Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MannKind8.07% -17.74% 8.68% Silverback Therapeutics N/A -29.62%-28.20% Do insiders & institutionals believe in MNKD or SBTX? 49.6% of MannKind shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 3.0% of MannKind shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, MNKD or SBTX? MannKind has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. SummaryMannKind beats Silverback Therapeutics on 16 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$488.59M$6.50B$5.09B$8.81BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-5.605.4594.6014.18Price / SalesN/A373.721,217.5288.10Price / CashN/A52.5939.4936.27Price / Book1.8310.266.956.35Net Income-$89.48M$153.22M$118.83M$225.71M7 Day Performance-3.76%-1.74%-1.52%-0.32%1 Month Performance-15.26%-7.22%-3.39%1.76%1 Year Performance183.47%31.69%32.17%27.70% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$13.55-1.7%N/A+192.8%$488.59MN/A-5.6083High Trading VolumeMNKDMannKind3.47 of 5 stars$6.95+1.0%$8.67+24.7%+83.0%$1.92B$198.96M98.29400Insider TradeIRONDisc Medicine3.1676 of 5 stars$63.99+2.3%$85.80+34.1%+22.4%$1.90BN/A0.0078Insider TradeAnalyst RevisionHRMYHarmony Biosciences4.7588 of 5 stars$33.13+1.0%$47.00+41.9%+18.1%$1.89B$582.02M15.64200NAMSNewAmsterdam Pharma2.9488 of 5 stars$20.35+1.7%$33.80+66.1%+110.6%$1.88B$14.09M0.0057Analyst ForecastInsider TradeNews CoverageHigh Trading VolumeEVOEvotec1.9387 of 5 stars$5.29-0.2%$5.93+12.2%-49.7%$1.87B$845.74M0.005,061GPCRStructure Therapeutics2.3001 of 5 stars$31.20-4.6%$86.80+178.2%-38.8%$1.79BN/A-42.84136Analyst RevisionARVNArvinas3.0931 of 5 stars$24.85+9.5%$61.08+145.8%+4.2%$1.71B$78.50M-5.21445Analyst ForecastShort Interest ↓News CoverageXNCRXencor3.5491 of 5 stars$24.14+1.8%$35.75+48.1%+19.3%$1.69B$168.34M-7.41280GLPGGalapagos1.2835 of 5 stars$25.34-1.2%$30.75+21.3%-31.4%$1.67B$259.40M0.001,123Analyst DowngradeShort Interest ↓News CoverageNRIXNurix Therapeutics2.7301 of 5 stars$23.01+1.6%$29.40+27.8%+247.8%$1.63B$76.99M0.00300 Related Companies and Tools Related Companies MNKD Alternatives IRON Alternatives HRMY Alternatives NAMS Alternatives EVO Alternatives GPCR Alternatives ARVN Alternatives XNCR Alternatives GLPG Alternatives NRIX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SBTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
